天臣医疗（688013.SH）11月14日在投资者互动平台表示，尊敬的投资者，您好！公司正在研发的集约 式智能手术平台及执行末端（MA）项目正按计划有序推进中，目前已完成生产线的工艺验证，正在进 行严格的产品各项技术性能验证，关于项目后续进展情况，公司将按相关法律法规要求及时履行信息披 露义务。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问公司的MA项目进展如何，预期何时可以开始医疗 器械注册申报？ ...

格隆汇11月14日丨天臣医疗(688013.SH)在投资者互动平台表示,公司正在研发的集约式智能手术平台及 执行末端（MA）项目正按计划有序推进中，目前已完成生产线的工艺验证，正在进行严格的产品各项 技术性能验证。 ...

Core Insights - The company plans to accelerate the development of innovative businesses such as smart DR solutions and AI grassroots healthcare through investments, mergers, strategic partnerships, and business synergies in 2025 and beyond [1] Group 1: Industry Trends - The medical device industry in China showed characteristics of deepening technology internally and extending markets externally in the first half of 2025, with continuous innovation and growth momentum [1] - Many listed companies are focusing on AI and robotics technologies, leading to significant breakthroughs and innovations [2] Group 2: Company Developments - Xiangsheng Medical has launched the Sono AI solution, achieving a full-chain intelligent upgrade in ultrasound examinations across various fields [2] - Tianchen Medical is developing an integrated intelligent surgical platform and plans to initiate registration for innovative medical devices [2] - Sanyou Medical has received approval for its spinal surgery robot and related intelligent products, continuing to deepen its surgical robot business layout [2] Group 3: International Expansion - Several medical device companies have made progress in expanding overseas markets, with notable achievements in global layout [3] - Tianchen Medical reported obtaining market access in three new countries and 14 overseas product registration certificates, with overseas revenue reaching 53.47 million yuan, accounting for 34.24% of total revenue [3] - Yirui Technology has made significant strides in the overseas dental market, focusing on localizing manufacturing in developing countries [3] - Microelectrophysiology reported over 40% year-on-year growth in international market revenue, with successful operations in multiple countries [3] - Tianzhihang has received EU CE certification for its orthopedic surgical navigation system and plans to develop differentiated strategies for various overseas markets [3]

Company Performance - In the first half of 2025, the company achieved revenue of 156 million yuan, representing a year-on-year growth of 17.66% [1] - The net profit attributable to shareholders was 48.21 million yuan, with a year-on-year increase of 67.10% [1] R&D and Product Development - The company focuses on key surgical procedures, with core products including various types of surgical staplers and support products, addressing clinical needs such as tissue separation, excision, organ function reconstruction, and intraoperative hemostasis [2] - The main revenue driver is the minimally invasive endoscopic products, which include disposable endoscopic cutting staplers and electric endoscopic cutting staplers, widely used in various minimally invasive surgeries [2] - R&D investment reached 18.89 million yuan in the first half of 2025, up 21.34% year-on-year, with R&D expenditure accounting for 12.10% of revenue [2] - The company applied for 11 new patents globally and received 53 new patent authorizations, including 44 core technology invention patents [2] Product Pipeline and Market Expansion - The company is accelerating its layout around "ultra-minimally invasive + intelligent" dual lines, with products like the "TSN electric stapler" already registered in two overseas countries [3] - The "third-generation endoscopic cutting stapler and nail warehouse" has completed multiple rounds of testing and is about to enter the registration process [3] - The company is also advancing its smart surgical platform project, which has made significant progress in key technologies and is entering the first product release and industrialization phase [3] Industry Outlook - The global medical device market is projected to reach 623 billion USD by 2024, with a compound annual growth rate (CAGR) of 6.9% from 2019 to 2024, and expected to grow to 869.7 billion USD by 2030 [4] - The demand for minimally invasive and robotic surgeries is driving significant growth in the surgical instrument sector, with the company well-positioned to benefit from this trend due to its technological and patent advantages [4] Strategic Initiatives - The company is enhancing its domestic and overseas dual-drive strategy, ensuring stable supply of selected products under national procurement policies while dynamically assessing market competition [5] - The company plans to issue a high dividend payout, distributing 5 yuan per 10 shares, totaling 40.33 million yuan, which accounts for 83.66% of the net profit attributable to shareholders for the first half of the year [5][6]